A Study of the Plasmodium Falciparum Malaria Vaccine Candidate Pfs48/45 in Matrix-M Adjuvant in the UK

Malaria Clinical Trial

Official title:

A Phase Ia Study to Assess Safety and Immunogenicity of the Plasmodium Falciparum Malaria Vaccine Candidate Pfs48/45 in Matrix-M Adjuvant in Healthy Adults Living in the UK

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05400746
• Other study ID #: VAC085
• Status: Recruiting
• Phase: Early Phase 1
• Start date: November 2, 2022
• Est. completion date: May 30, 2023

Study information

• Verified date: June 2022
• Source: University of Oxford
• Contact: Volunteer Recruitment Co-ordinator Volunteer Recruitment Co-ordi
• Phone: 01865 611424
• Email: vaccinetrials[@]ndm.ox.ac.uk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open label, single-site, first-in-human, dose-escalation Phase Ia study to assess safety and immunogenicity of the Plasmodium falciparum malaria vaccine candidate Pfs48/45 in Matrix-M adjuvant in healthy adults living in the UK

Description:

Volunteers will be recruited into one of three groups (n=8-10 per group) at the Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Oxford over approximately 12 months. All volunteers will receive three dose of Pfs48/45 in 50 µg Matrix-M, administered intramuscularly and given four weeks apart. Enrolment will be staggered with clinical and safety reviews, follow-up visits and monitoring via a diary card.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: May 30, 2023
• Est. primary completion date: May 30, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Healthy adult aged 18 to 45 years.

• Able and willing (in the Investigator's opinion) to comply with all study requirements.

• Willing to allow the Investigators to discuss the volunteer's medical history with their GP.

• Volunteers with the potential to become pregnant only: must practice continuous effective contraception for the duration of the study (see section 10.10).

• Agreement to refrain from blood donation for the duration of the study.

• Able and willing to provide written informed consent to participate in the trial

Exclusion Criteria:

• History of clinical malaria (any species).

• Travel to a clearly malaria endemic locality during the study period or within the preceding six months.

• Use of immunoglobulins or blood products (e.g., blood transfusion) in the last three months.

• Receipt of any vaccine in the 30 days preceding enrolment, or planned receipt of any other vaccine within 30 days following each study vaccination, with the exception of COVID-19 vaccines, which should not be received between 14 days before to 7 days after any study vaccination.

• Receipt of an investigational product in the 30 days preceding enrolment, or planned receipt during the study period.

• Concurrent involvement in another clinical trial or planned involvement during the study period.

• Prior receipt of an investigational vaccine likely to impact on interpretation of the trial data, as assessed by the Investigator.

• Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed).

• History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.

• Any history of anaphylaxis in reaction to vaccinations.

• Pregnancy, lactation or intention to become pregnant during the study.

• History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ).

• History of serious psychiatric condition that may affect participation in the study.

• Any other serious chronic illness requiring hospital specialist supervision.

• Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 25 standard UK units every week.

• Suspected or known injecting drug abuse in the 5 years preceding enrolment.

• Hepatitis B surface antigen (HBsAg) detected in serum.

• Seropositive for hepatitis C virus (antibodies to HCV) at screening (unless volunteer has taken part in a prior hepatitis C vaccine study with confirmed negative HCV antibodies prior to participation in that study, and negative HCV ribonucleic acid (RNA) PCR at screening for this study).

• Volunteers unable to be closely followed for social, geographic or psychological reasons.

• Any clinically significant abnormal finding on biochemistry or haematology blood tests, urinalysis or clinical examination. In the event of abnormal test results, confirmatory repeat tests will be requested. Procedures for identifying laboratory values meeting exclusion criteria are shown in SOP VC027.

• Any other significant disease, disorder, or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data.

• Inability of the study team to contact the volunteer's GP to confirm medical history

Related Conditions & MeSH terms

• Malaria
• Malaria, Falciparum
• Plasmodium Falciparum

Intervention

Biological:
• Pfs48/45 in Matrix-M
Three doses of Pfs48/45 in Matrix-M at different doses

Locations

Country	Name	City	State
United Kingdom	CCVTM, University of Oxford	Oxford

Sponsors (1)

Lead Sponsor	Collaborator
University of Oxford

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To assess safety and tolerability of the Pfs48/45 with Matrix-M vaccine at various doses in healthy adult volunteers by assessing the occurrence of solicited local reactogenicity signs and symptoms for 7 days following each vaccination	Occurrence of solicited local reactogenicity signs and symptoms for 7 days following each vaccination using e-diaries, clinical review, clinical examination (including observations) and laboratory results	7 days following each vaccination
Primary	To assess safety and tolerability of the Pfs48/45 with Matrix-M vaccine at various doses in healthy adult volunteers by assessing the occurrence of solicited systemic reactogenicity signs and symptoms for 7 days following each vaccination	Occurrence of solicited systemic reactogenicity signs and symptoms for 7 days following each vaccination using e-diaries, clinical review, clinical examination (including observations) and laboratory results	7 days following each vaccination
Primary	To assess safety and tolerability of the Pfs48/45 with Matrix-M vaccine at various doses in healthy adult volunteers by assessing the occurrence of unsolicited adverse events (AEs) for 28 days following the vaccination	Occurrence of unsolicited adverse events (AEs) for 28 days following the vaccination using e-diaries, clinical review, clinical examination (including observations) and laboratory results	28 days following the vaccination
Primary	To assess safety and tolerability of the Pfs48/45 with Matrix-M vaccine at various doses in healthy adult volunteers. assessed through the number of participants with abnormal laboratory test results	Occurrence of change from baseline laboratory tests	28 days following vaccination
Primary	To assess safety and tolerability of the Pfs48/45 with Matrix-M vaccine at various doses in healthy adult volunteers assessed through the number of participants with serious adverse events	Occurrence of serious adverse events and will be presented according to local grading scales	Whole duration of the study (8 months following initial trial vaccination)
Primary	To assess safety and tolerability of the Pfs48/45 with Matrix-M vaccine at various doses in healthy adult volunteers.	Occurrence of AEs of special interest and will be presented according to local grading scales and will be described in detail	Whole duration of the study (8 months following initial trial vaccination)
Secondary	To assess the humoral immunogenicity of the Pfs48/45 with Matrix-M vaccine, when administered to healthy adult volunteers as assessed by humoral responses to the Pfs48/45 protein	Antibody responses to the Pfs48/45 protein will be assessed through total IgG isotypes and avidity	Days 1, 29, 57, 140 and 240
Secondary	To assess the cellular immunogenicity of the Pfs48/45 with Matrix-M vaccine, when administered to healthy adult volunteers as assessed by cellular responses to the Pfs48/45 protein	T cell responses to Pfs48/45 will be assessed by ex vivo enzyme-linked immunospot assays (ELISpot)	Days 1, 29, 57, 140 and 240
Secondary	To assess ex vivo efficacy of the Pfs48/45 with Matrix-M vaccine, when administered to healthy adult volunteers using direct membrane feeding assays as assessed by transmission-reducing activity	Transmission-reducing activity	Days 1, 29, 57, 140 and 240
Secondary	To assess ex vivo efficacy of the Pfs48/45 with Matrix-M vaccine, when administered to healthy adult volunteers using direct membrane feeding assays as assessed by transmission-blocking activity	Transmission-blocking activity	Days 1, 29, 57, 140 and 240